Nanosphere Inc: (NASD: NSPH)
$3.79
0.09 (2.43%)
Volume 820,641
May 23 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 3.45 - 3.80 |
| 52wk Low - High | 1.63 - 3.89 |
| Previous Close | 3.70 |
| Avg. Volume | 605,430 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 207.53 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 2.46 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.58 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
95 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.58 |
| Current Quarter Estimate | -0.15 |
| Most Accurate Estimate | -0.15 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -0.63 |
| Expected Earnings Growth | NA |
Company Description
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(r) System for direct genomic and ultra-sensitive protein detection. It is easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.15 | -0.14 | -0.58 | -0.44 |
| Number of Estimates | 3 | 3 | 4 | 4 |
| Low Estimate | -0.16 | -0.15 | -0.61 | -0.57 |
| High Estimate | -0.15 | -0.13 | -0.55 | NA |
| Year Ago EPS | -0.19 | -0.16 | -0.67 | -0.58 |
| EPS Growth | 19.30% | 10.42% | 13.06% | 24.03% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| NANOSPHERE INC | NSPH | 3.70 | |
|
| ANIKA THERAPEUT | ANIK | 13.75 | |
|
| GENTIUM SPA-ADR | GENT | 8.79 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACADIA PHARMA | ACAD | 13.42 | |
|
| ACHILLION PHARM | ACHN | 7.74 | |
|
| ADDEX THERA LTD | ADDXF | 6.62 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| AFFYMAX INC | AFFY | 1.40 | |
|
| ALEXION PHARMA | ALXN | 100.57 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
FDA Clears GenMark's Newest Test
Sep 13, 2012
GenMark Raises Guidance
Jun 13, 2012
Report for NSPH
May 21, 2013
Financials
| EPS TTM | -0.63 |
| Sales | 5 |
| Net Income | -33 |
| Price/Earnings | NA |
| Price/Book | 6.09 |
| Price/Cash Flow | NA |
| Price/Sales | 33.76 |
News
Nanosphere reports higher Q1 net loss, provides outlook for 2013 - Datamonitor
May 21, 2013
Hot Stock: Nanosphere, Shares Gain 5.8% (NSPH) - Financial News Network Online - Market Movers
May 20, 2013
Traders Get Bullish on Shares of Nanosphere, Shares Up 5.0% (NSPH) - Comtex Smartrend(R)
May 20, 2013
New Validation and Clinical Outcome Data From Several Studies onNanosphere's Gram-Positive and Gram-Negative Blood Culture Tests toBe Presented at ASM 2013 - Marketwire
May 16, 2013
Nanosphere to Present at UBS Global Healthcare Conference - Marketwire
May 15, 2013
ARSD, CPL, MLNX, ESSA, NSPH, AGNC Are Seasonally Ripe To Go Up In the Next Five Weeks - M2
May 14, 2013
Benzinga`s Top Pre-Market Gainers - Benzinga
May 14, 2013
Morning Market Movers - Benzinga
May 14, 2013
Broker Recommendations
| Current ABR | 1.40 |
| ABR (Last Week) | 1.40 |
| # of recs in ABR | 5 |
| Average Target Price | 3.65 |
| Industry Rank by ABR | 95 out of 265 |
| Rank in Industry | 36 out of 152 |
